NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 175
(Total Views: 165)
Posted On: 05/25/2023 4:05:19 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Granted Key Patent for Use in Innovative System Designed to Help Evaluate Cardiac Symptoms
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office informing the company of the key patent, which relates to the initial AI capability in the form of an expert system for the AIMIGo System. The patent, titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment,” outlines a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with a patient’s symptoms and cardiac risk factors, resulting in a cardiac risk score and providing simplified diagnostic information and actionable instructions for the patient. According to the announcement, HeartBeam has developed the personal, portable and easy-to-use VECG solution to support patients and clinicians in evaluating cardiac symptoms. “We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives. This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices.”
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office informing the company of the key patent, which relates to the initial AI capability in the form of an expert system for the AIMIGo System. The patent, titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment,” outlines a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with a patient’s symptoms and cardiac risk factors, resulting in a cardiac risk score and providing simplified diagnostic information and actionable instructions for the patient. According to the announcement, HeartBeam has developed the personal, portable and easy-to-use VECG solution to support patients and clinicians in evaluating cardiac symptoms. “We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives. This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices.”
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
(0)
(0)